Drugs Made In America Acquisition Corp.
DMAAU- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002028614
No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $122.3K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Drugs Made In America Acquisition Corp. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −6 vs. Q1 2025
- Shares held
- 986.1K
- −2.30M (−70.0%) vs. Q1 2025
- Total value
- $10.2M
- −$23.2M (−69.5%) vs. Q1 2025
- New holders
- 1
- 2 more added
- Sold out
- 7
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMAAU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $122.3K |
| Q1 2026 | 2 | $121.0K |
| Q4 2025 | 5 | $5.77M |
| Q3 2025 | 8 | $6.73M |
| Q2 2025 | 9 | $10.2M |
| Q1 2025 | 15 | $33.4M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Drugs Made In America Acquisition Corp.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rivernorth Capital Management, LLC | 420,498 | $4.34M | 0.24% | 00.0% | Unchanged |
| Context Capital Management, LLC | 250,000 | $2.58M | 0.09% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 130,000 | $1.34M | 0.02% | 00.0% | Unchanged |
| Bulldog Investors, LLP | 57,300 | $591.3K | 0.15% | −72,964−56.0% | Reduced |
| Clear Street LLC | 45,920 | $473.9K | 0.00% | +40,071+685.1% | Added |
| Robinson Capital Management, LLC | 30,000 | $309.6K | 0.13% | +30,000 | New |
| Tuttle Tactical Management | 20,000 | $206.4K | 0.85% | −20,000−50.0% | Reduced |
| UBS Group AG | 18,385 | $189.7K | 0.00% | +107+0.6% | Added |
| Citadel Advisors LLC | 14,026 | $144.7K | 0.00% | −1,727−11.0% | Reduced |
| Heights Capital Management, Inc | 0 | $0 | 0.00% | −650,000−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −603,750−100.0% | Sold out |
| Westchester Capital Management, LLC | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −234,831−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Murchinson Ltd. | 0 | $0 | 0.00% | −90,000−100.0% | Sold out |